Related Experiment Video
Updated: May 2, 2026
08:47
Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats
Published on: November 8, 2018
11.2K
The modified atkins diet in refractory epilepsy
Suvasini Sharma1, Puneet Jain1
1Division of Pediatric Neurology, Department of Pediatrics, Lady Hardinge Medical College and Associated Kalawati Saran Children's Hospital, New Delhi 110001, India.
Epilepsy Research and Treatment
|March 15, 2014
Summary
The modified Atkins diet, a less restrictive ketogenic diet, shows effectiveness and tolerability for managing refractory epilepsy. This dietary approach is suitable for outpatient initiation without fasting.
Area of Science:
- Neurology
- Dietary Therapies
- Epilepsy Management
Background:
- Refractory epilepsy presents significant treatment challenges.
- The ketogenic diet is an established therapy for epilepsy.
- A less restrictive ketogenic diet may improve patient adherence and outcomes.
Purpose of the Study:
- To review the efficacy and tolerability of the modified Atkins diet (MAD) in patients with refractory epilepsy.
- To discuss the practical application and benefits of MAD in clinical settings.
Main Methods:
- Literature review of studies investigating the modified Atkins diet for refractory epilepsy.
- Analysis of reported efficacy, tolerability, and adherence data.
Main Results:
- The modified Atkins diet demonstrates good efficacy in reducing seizure frequency in refractory epilepsy.
- Patients generally tolerate the modified Atkins diet well, with manageable side effects.
- Outpatient initiation without a preceding fast is feasible and effective.
Conclusions:
- The modified Atkins diet is a viable and effective therapeutic option for refractory epilepsy.
- Its less restrictive nature compared to the classic ketogenic diet enhances tolerability and adherence.
- Further research should explore long-term outcomes and specific patient populations.
More Related Videos
Related Concept Videos
01:14Antiepileptic Drugs: Glutamate Antagonists
1.3K
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.3K
01:24Epilepsy and Seizures: Overview
1.7K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.7K
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
1.7K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.7K
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
1.2K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.2K
01:08Antiepileptic Drugs: Sodium Channel Blockers
2.4K
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
2.4K
01:20Antiepileptic Drugs: Potassium Channel Activators
1.0K
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
1.0K